SANGAMO THERAPEUTICS INC (SGMO) Stock News

USA - NASDAQ:SGMO - US8006771062 - Common Stock

0.5127 USD

0 (-0.29%)

Last: 9/17/2025, 8:03:38 PM

0.5301 USD

+0.02 (+3.39%)

After Hours: 9/17/2025, 8:03:38 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SGMO Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

a month ago - By: Zacks Investment Research

What Makes Sangamo (SGMO) a New Buy Stock

a month ago - By: Zacks Investment Research - Mentions: CRVO

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

a month ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

a month ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

3 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

4 months ago - By: Benzinga - Mentions: HALO RGC AXDX APYX ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

4 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

4 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

4 months ago - By: Zacks Investment Research - Mentions: ARMP

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

4 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

4 months ago - By: Zacks Investment Research - Mentions: NVAX

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

4 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

4 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

5 months ago - By: Zacks Investment Research - Mentions: RGNX

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

5 months ago - By: Zacks Investment Research - Mentions: QGEN

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

5 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

6 months ago - By: Stocktwits - Mentions: LLY XLV

Eli Lilly Stock Drops As Trump Tariff Chaos Hits Markets, But Retail Finds Comfort In Big Pharma’s Exemption

6 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System